nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydroflumethiazide—KCNMA1—pulmonary artery—sarcoma	0.0719	0.133	CbGeAlD
Hydroflumethiazide—SLC12A1—appendage—sarcoma	0.0412	0.0759	CbGeAlD
Hydroflumethiazide—CA2—periosteum—sarcoma	0.0301	0.0554	CbGeAlD
Hydroflumethiazide—CA5B—mammary gland—sarcoma	0.0156	0.0288	CbGeAlD
Hydroflumethiazide—CA14—seminal vesicle—sarcoma	0.0143	0.0264	CbGeAlD
Hydroflumethiazide—KCNMA1—myometrium—sarcoma	0.0129	0.0237	CbGeAlD
Hydroflumethiazide—SLC12A1—hematopoietic system—sarcoma	0.0122	0.0225	CbGeAlD
Hydroflumethiazide—ATP1A1—mammary gland—sarcoma	0.0117	0.0215	CbGeAlD
Hydroflumethiazide—KCNMA1—hematopoietic system—sarcoma	0.0111	0.0204	CbGeAlD
Hydroflumethiazide—Hyperuricaemia—Thiotepa—sarcoma	0.0111	0.0242	CcSEcCtD
Hydroflumethiazide—Blood uric acid increased—Thiotepa—sarcoma	0.0104	0.0228	CcSEcCtD
Hydroflumethiazide—CA14—cardiac atrium—sarcoma	0.0103	0.019	CbGeAlD
Hydroflumethiazide—CA12—connective tissue—sarcoma	0.0102	0.0188	CbGeAlD
Hydroflumethiazide—Hyperuricaemia—Vincristine—sarcoma	0.00981	0.0214	CcSEcCtD
Hydroflumethiazide—KCNMA1—smooth muscle tissue—sarcoma	0.00974	0.018	CbGeAlD
Hydroflumethiazide—Aplastic anaemia—Dactinomycin—sarcoma	0.00956	0.0209	CcSEcCtD
Hydroflumethiazide—Hyperuricaemia—Mitoxantrone—sarcoma	0.00955	0.0209	CcSEcCtD
Hydroflumethiazide—CA5B—hematopoietic system—sarcoma	0.00952	0.0175	CbGeAlD
Hydroflumethiazide—CA9—tendon—sarcoma	0.00949	0.0175	CbGeAlD
Hydroflumethiazide—Blood uric acid increased—Vincristine—sarcoma	0.00926	0.0203	CcSEcCtD
Hydroflumethiazide—Blood uric acid increased—Mitoxantrone—sarcoma	0.00902	0.0197	CcSEcCtD
Hydroflumethiazide—CA14—tendon—sarcoma	0.009	0.0166	CbGeAlD
Hydroflumethiazide—CA1—hematopoietic system—sarcoma	0.0084	0.0155	CbGeAlD
Hydroflumethiazide—KCNMA1—uterus—sarcoma	0.00836	0.0154	CbGeAlD
Hydroflumethiazide—ATP1A1—myometrium—sarcoma	0.00828	0.0153	CbGeAlD
Hydroflumethiazide—ATP1A1—embryo—sarcoma	0.00796	0.0147	CbGeAlD
Hydroflumethiazide—Hyperuricaemia—Etoposide—sarcoma	0.00794	0.0174	CcSEcCtD
Hydroflumethiazide—CA9—testis—sarcoma	0.00786	0.0145	CbGeAlD
Hydroflumethiazide—Blood uric acid increased—Etoposide—sarcoma	0.0075	0.0164	CcSEcCtD
Hydroflumethiazide—ATP1A1—seminal vesicle—sarcoma	0.00748	0.0138	CbGeAlD
Hydroflumethiazide—CA5B—cardiac atrium—sarcoma	0.00723	0.0133	CbGeAlD
Hydroflumethiazide—ATP1A1—hematopoietic system—sarcoma	0.00711	0.0131	CbGeAlD
Hydroflumethiazide—CA14—liver—sarcoma	0.00705	0.013	CbGeAlD
Hydroflumethiazide—CA4—seminal vesicle—sarcoma	0.00691	0.0127	CbGeAlD
Hydroflumethiazide—ATP1A1—connective tissue—sarcoma	0.00684	0.0126	CbGeAlD
Hydroflumethiazide—SLC12A1—testis—sarcoma	0.00669	0.0123	CbGeAlD
Hydroflumethiazide—CA5B—tendon—sarcoma	0.0063	0.0116	CbGeAlD
Hydroflumethiazide—ATP1A1—smooth muscle tissue—sarcoma	0.00626	0.0115	CbGeAlD
Hydroflumethiazide—ATP1A1—skin of body—sarcoma	0.00618	0.0114	CbGeAlD
Hydroflumethiazide—CA2—embryo—sarcoma	0.0061	0.0112	CbGeAlD
Hydroflumethiazide—KCNMA1—testis—sarcoma	0.00606	0.0112	CbGeAlD
Hydroflumethiazide—CA1—lymphoid tissue—sarcoma	0.00592	0.0109	CbGeAlD
Hydroflumethiazide—Hyperglycaemia—Thiotepa—sarcoma	0.00581	0.0127	CcSEcCtD
Hydroflumethiazide—KCNMA1—liver—sarcoma	0.00573	0.0106	CbGeAlD
Hydroflumethiazide—CA2—seminal vesicle—sarcoma	0.00573	0.0106	CbGeAlD
Hydroflumethiazide—Jaundice—Thiotepa—sarcoma	0.00559	0.0122	CcSEcCtD
Hydroflumethiazide—CA2—hematopoietic system—sarcoma	0.00545	0.01	CbGeAlD
Hydroflumethiazide—ATP1A1—cardiac atrium—sarcoma	0.0054	0.00995	CbGeAlD
Hydroflumethiazide—CA1—bone marrow—sarcoma	0.00539	0.00993	CbGeAlD
Hydroflumethiazide—ATP1A1—uterus—sarcoma	0.00537	0.0099	CbGeAlD
Hydroflumethiazide—Agranulocytosis—Thiotepa—sarcoma	0.00536	0.0117	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Dactinomycin—sarcoma	0.00532	0.0116	CcSEcCtD
Hydroflumethiazide—CA2—connective tissue—sarcoma	0.00524	0.00967	CbGeAlD
Hydroflumethiazide—CA5B—testis—sarcoma	0.00521	0.00961	CbGeAlD
Hydroflumethiazide—Photosensitivity reaction—Vincristine—sarcoma	0.00521	0.0114	CcSEcCtD
Hydroflumethiazide—Glycosuria—Epirubicin—sarcoma	0.0051	0.0111	CcSEcCtD
Hydroflumethiazide—Hyperglycaemia—Mitoxantrone—sarcoma	0.00501	0.011	CcSEcCtD
Hydroflumethiazide—ATP1A1—lymphoid tissue—sarcoma	0.005	0.00922	CbGeAlD
Hydroflumethiazide—CA4—cardiac atrium—sarcoma	0.00499	0.00919	CbGeAlD
Hydroflumethiazide—Jaundice—Mitoxantrone—sarcoma	0.00483	0.0106	CcSEcCtD
Hydroflumethiazide—Cramp muscle—Etoposide—sarcoma	0.00482	0.0105	CcSEcCtD
Hydroflumethiazide—CA2—smooth muscle tissue—sarcoma	0.0048	0.00884	CbGeAlD
Hydroflumethiazide—CA2—skin of body—sarcoma	0.00474	0.00873	CbGeAlD
Hydroflumethiazide—Glycosuria—Doxorubicin—sarcoma	0.00472	0.0103	CcSEcCtD
Hydroflumethiazide—ATP1A1—tendon—sarcoma	0.0047	0.00867	CbGeAlD
Hydroflumethiazide—Jaundice cholestatic—Epirubicin—sarcoma	0.0047	0.0103	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Mitoxantrone—sarcoma	0.00463	0.0101	CcSEcCtD
Hydroflumethiazide—ATP1A1—bone marrow—sarcoma	0.00456	0.0084	CbGeAlD
Hydroflumethiazide—Hyperuricaemia—Epirubicin—sarcoma	0.00445	0.00973	CcSEcCtD
Hydroflumethiazide—KCNMA1—lymph node—sarcoma	0.00439	0.0081	CbGeAlD
Hydroflumethiazide—CA1—liver—sarcoma	0.00435	0.00802	CbGeAlD
Hydroflumethiazide—Jaundice cholestatic—Doxorubicin—sarcoma	0.00435	0.00951	CcSEcCtD
Hydroflumethiazide—CA4—tendon—sarcoma	0.00435	0.00801	CbGeAlD
Hydroflumethiazide—CA4—bone marrow—sarcoma	0.00421	0.00776	CbGeAlD
Hydroflumethiazide—Blood uric acid increased—Epirubicin—sarcoma	0.00421	0.0092	CcSEcCtD
Hydroflumethiazide—CA2—cardiac atrium—sarcoma	0.00414	0.00762	CbGeAlD
Hydroflumethiazide—Agitation—Thiotepa—sarcoma	0.00412	0.00901	CcSEcCtD
Hydroflumethiazide—Hyperuricaemia—Doxorubicin—sarcoma	0.00412	0.00901	CcSEcCtD
Hydroflumethiazide—Jaundice—Etoposide—sarcoma	0.00402	0.00878	CcSEcCtD
Hydroflumethiazide—Leukopenia—Thiotepa—sarcoma	0.00401	0.00878	CcSEcCtD
Hydroflumethiazide—Leukopenia—Dactinomycin—sarcoma	0.00398	0.00871	CcSEcCtD
Hydroflumethiazide—ATP1A1—testis—sarcoma	0.00389	0.00718	CbGeAlD
Hydroflumethiazide—Blood uric acid increased—Doxorubicin—sarcoma	0.00389	0.00851	CcSEcCtD
Hydroflumethiazide—Aplastic anaemia—Epirubicin—sarcoma	0.00388	0.00848	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Etoposide—sarcoma	0.00385	0.00841	CcSEcCtD
Hydroflumethiazide—CA2—lymphoid tissue—sarcoma	0.00383	0.00707	CbGeAlD
Hydroflumethiazide—CA5B—lymph node—sarcoma	0.00378	0.00697	CbGeAlD
Hydroflumethiazide—ATP1A1—liver—sarcoma	0.00368	0.00679	CbGeAlD
Hydroflumethiazide—Agitation—Vincristine—sarcoma	0.00365	0.00799	CcSEcCtD
Hydroflumethiazide—CA2—tendon—sarcoma	0.0036	0.00664	CbGeAlD
Hydroflumethiazide—CA4—testis—sarcoma	0.0036	0.00663	CbGeAlD
Hydroflumethiazide—Aplastic anaemia—Doxorubicin—sarcoma	0.00359	0.00784	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Thiotepa—sarcoma	0.00358	0.00783	CcSEcCtD
Hydroflumethiazide—Vertigo—Vincristine—sarcoma	0.00357	0.00781	CcSEcCtD
Hydroflumethiazide—Leukopenia—Vincristine—sarcoma	0.00356	0.00778	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Dactinomycin—sarcoma	0.00356	0.00778	CcSEcCtD
Hydroflumethiazide—CA2—bone marrow—sarcoma	0.00349	0.00644	CbGeAlD
Hydroflumethiazide—Anorexia—Thiotepa—sarcoma	0.00349	0.00763	CcSEcCtD
Hydroflumethiazide—Leukopenia—Mitoxantrone—sarcoma	0.00347	0.00758	CcSEcCtD
Hydroflumethiazide—Anorexia—Dactinomycin—sarcoma	0.00346	0.00757	CcSEcCtD
Hydroflumethiazide—Photosensitivity—Epirubicin—sarcoma	0.00342	0.00747	CcSEcCtD
Hydroflumethiazide—Vascular purpura—Epirubicin—sarcoma	0.00335	0.00733	CcSEcCtD
Hydroflumethiazide—CA1—lymph node—sarcoma	0.00334	0.00615	CbGeAlD
Hydroflumethiazide—Decreased appetite—Thiotepa—sarcoma	0.00318	0.00696	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Vincristine—sarcoma	0.00318	0.00695	CcSEcCtD
Hydroflumethiazide—Photosensitivity—Doxorubicin—sarcoma	0.00316	0.00691	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Dactinomycin—sarcoma	0.00316	0.0069	CcSEcCtD
Hydroflumethiazide—Constipation—Thiotepa—sarcoma	0.00313	0.00684	CcSEcCtD
Hydroflumethiazide—Purpura—Epirubicin—sarcoma	0.00311	0.0068	CcSEcCtD
Hydroflumethiazide—Vascular purpura—Doxorubicin—sarcoma	0.0031	0.00678	CcSEcCtD
Hydroflumethiazide—Muscle spasms—Etoposide—sarcoma	0.0031	0.00677	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Mitoxantrone—sarcoma	0.00309	0.00677	CcSEcCtD
Hydroflumethiazide—Anorexia—Vincristine—sarcoma	0.00309	0.00676	CcSEcCtD
Hydroflumethiazide—Anorexia—Mitoxantrone—sarcoma	0.00301	0.00659	CcSEcCtD
Hydroflumethiazide—CA2—testis—sarcoma	0.00298	0.0055	CbGeAlD
Hydroflumethiazide—Urticaria—Thiotepa—sarcoma	0.00291	0.00636	CcSEcCtD
Hydroflumethiazide—Vertigo—Etoposide—sarcoma	0.00289	0.00633	CcSEcCtD
Hydroflumethiazide—Leukopenia—Etoposide—sarcoma	0.00288	0.0063	CcSEcCtD
Hydroflumethiazide—Purpura—Doxorubicin—sarcoma	0.00288	0.00629	CcSEcCtD
Hydroflumethiazide—ATP1A1—lymph node—sarcoma	0.00282	0.0052	CbGeAlD
Hydroflumethiazide—CA2—liver—sarcoma	0.00282	0.0052	CbGeAlD
Hydroflumethiazide—Decreased appetite—Vincristine—sarcoma	0.00282	0.00617	CcSEcCtD
Hydroflumethiazide—Constipation—Vincristine—sarcoma	0.00278	0.00607	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Mitoxantrone—sarcoma	0.00275	0.00601	CcSEcCtD
Hydroflumethiazide—Orthostatic hypotension—Epirubicin—sarcoma	0.00274	0.00599	CcSEcCtD
Hydroflumethiazide—Constipation—Mitoxantrone—sarcoma	0.0027	0.00591	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Thiotepa—sarcoma	0.0027	0.0059	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Dactinomycin—sarcoma	0.00268	0.00585	CcSEcCtD
Hydroflumethiazide—Asthenia—Thiotepa—sarcoma	0.00263	0.00574	CcSEcCtD
Hydroflumethiazide—CA4—lymph node—sarcoma	0.00261	0.00481	CbGeAlD
Hydroflumethiazide—Asthenia—Dactinomycin—sarcoma	0.00261	0.0057	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Etoposide—sarcoma	0.00257	0.00563	CcSEcCtD
Hydroflumethiazide—Pancreatitis—Epirubicin—sarcoma	0.00254	0.00555	CcSEcCtD
Hydroflumethiazide—Orthostatic hypotension—Doxorubicin—sarcoma	0.00253	0.00554	CcSEcCtD
Hydroflumethiazide—Urticaria—Mitoxantrone—sarcoma	0.00251	0.00549	CcSEcCtD
Hydroflumethiazide—Anorexia—Etoposide—sarcoma	0.00251	0.00548	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Thiotepa—sarcoma	0.0025	0.00547	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Dactinomycin—sarcoma	0.00249	0.00543	CcSEcCtD
Hydroflumethiazide—Dizziness—Thiotepa—sarcoma	0.00242	0.00529	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Vincristine—sarcoma	0.00239	0.00523	CcSEcCtD
Hydroflumethiazide—Photosensitivity reaction—Epirubicin—sarcoma	0.00237	0.00517	CcSEcCtD
Hydroflumethiazide—Pancreatitis—Doxorubicin—sarcoma	0.00235	0.00514	CcSEcCtD
Hydroflumethiazide—Hyperglycaemia—Epirubicin—sarcoma	0.00234	0.00511	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Mitoxantrone—sarcoma	0.00233	0.00509	CcSEcCtD
Hydroflumethiazide—Asthenia—Vincristine—sarcoma	0.00233	0.00509	CcSEcCtD
Hydroflumethiazide—Vomiting—Thiotepa—sarcoma	0.00233	0.00509	CcSEcCtD
Hydroflumethiazide—Vomiting—Dactinomycin—sarcoma	0.00231	0.00505	CcSEcCtD
Hydroflumethiazide—Rash—Thiotepa—sarcoma	0.00231	0.00504	CcSEcCtD
Hydroflumethiazide—Dermatitis—Thiotepa—sarcoma	0.00231	0.00504	CcSEcCtD
Hydroflumethiazide—Headache—Thiotepa—sarcoma	0.00229	0.00501	CcSEcCtD
Hydroflumethiazide—Rash—Dactinomycin—sarcoma	0.00229	0.00501	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Etoposide—sarcoma	0.00229	0.005	CcSEcCtD
Hydroflumethiazide—Asthenia—Mitoxantrone—sarcoma	0.00227	0.00496	CcSEcCtD
Hydroflumethiazide—Jaundice—Epirubicin—sarcoma	0.00225	0.00492	CcSEcCtD
Hydroflumethiazide—Constipation—Etoposide—sarcoma	0.00225	0.00491	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Vincristine—sarcoma	0.00222	0.00485	CcSEcCtD
Hydroflumethiazide—Photosensitivity reaction—Doxorubicin—sarcoma	0.00219	0.00478	CcSEcCtD
Hydroflumethiazide—Nausea—Thiotepa—sarcoma	0.00217	0.00475	CcSEcCtD
Hydroflumethiazide—CA2—lymph node—sarcoma	0.00216	0.00399	CbGeAlD
Hydroflumethiazide—Hyperglycaemia—Doxorubicin—sarcoma	0.00216	0.00473	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Mitoxantrone—sarcoma	0.00216	0.00473	CcSEcCtD
Hydroflumethiazide—Nausea—Dactinomycin—sarcoma	0.00216	0.00472	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Epirubicin—sarcoma	0.00216	0.00471	CcSEcCtD
Hydroflumethiazide—Dizziness—Vincristine—sarcoma	0.00215	0.00469	CcSEcCtD
Hydroflumethiazide—Urticaria—Etoposide—sarcoma	0.00209	0.00457	CcSEcCtD
Hydroflumethiazide—Jaundice—Doxorubicin—sarcoma	0.00208	0.00456	CcSEcCtD
Hydroflumethiazide—Vomiting—Vincristine—sarcoma	0.00206	0.00451	CcSEcCtD
Hydroflumethiazide—Rash—Vincristine—sarcoma	0.00205	0.00447	CcSEcCtD
Hydroflumethiazide—Dermatitis—Vincristine—sarcoma	0.00204	0.00447	CcSEcCtD
Hydroflumethiazide—Headache—Vincristine—sarcoma	0.00203	0.00444	CcSEcCtD
Hydroflumethiazide—Vomiting—Mitoxantrone—sarcoma	0.00201	0.00439	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Doxorubicin—sarcoma	0.002	0.00436	CcSEcCtD
Hydroflumethiazide—Rash—Mitoxantrone—sarcoma	0.00199	0.00436	CcSEcCtD
Hydroflumethiazide—Dermatitis—Mitoxantrone—sarcoma	0.00199	0.00435	CcSEcCtD
Hydroflumethiazide—Headache—Mitoxantrone—sarcoma	0.00198	0.00433	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Etoposide—sarcoma	0.00194	0.00423	CcSEcCtD
Hydroflumethiazide—Nausea—Vincristine—sarcoma	0.00193	0.00421	CcSEcCtD
Hydroflumethiazide—Asthenia—Etoposide—sarcoma	0.00189	0.00412	CcSEcCtD
Hydroflumethiazide—Nausea—Mitoxantrone—sarcoma	0.00188	0.0041	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Etoposide—sarcoma	0.0018	0.00393	CcSEcCtD
Hydroflumethiazide—Dizziness—Etoposide—sarcoma	0.00174	0.0038	CcSEcCtD
Hydroflumethiazide—Muscle spasms—Epirubicin—sarcoma	0.00174	0.0038	CcSEcCtD
Hydroflumethiazide—Vomiting—Etoposide—sarcoma	0.00167	0.00365	CcSEcCtD
Hydroflumethiazide—Agitation—Epirubicin—sarcoma	0.00166	0.00363	CcSEcCtD
Hydroflumethiazide—Rash—Etoposide—sarcoma	0.00166	0.00362	CcSEcCtD
Hydroflumethiazide—Dermatitis—Etoposide—sarcoma	0.00166	0.00362	CcSEcCtD
Hydroflumethiazide—Headache—Etoposide—sarcoma	0.00165	0.0036	CcSEcCtD
Hydroflumethiazide—Vertigo—Epirubicin—sarcoma	0.00162	0.00355	CcSEcCtD
Hydroflumethiazide—Leukopenia—Epirubicin—sarcoma	0.00162	0.00353	CcSEcCtD
Hydroflumethiazide—Muscle spasms—Doxorubicin—sarcoma	0.00161	0.00351	CcSEcCtD
Hydroflumethiazide—Nausea—Etoposide—sarcoma	0.00156	0.00341	CcSEcCtD
Hydroflumethiazide—Agitation—Doxorubicin—sarcoma	0.00154	0.00336	CcSEcCtD
Hydroflumethiazide—Vertigo—Doxorubicin—sarcoma	0.0015	0.00328	CcSEcCtD
Hydroflumethiazide—Leukopenia—Doxorubicin—sarcoma	0.0015	0.00327	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Epirubicin—sarcoma	0.00144	0.00315	CcSEcCtD
Hydroflumethiazide—Anorexia—Epirubicin—sarcoma	0.0014	0.00307	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Doxorubicin—sarcoma	0.00134	0.00292	CcSEcCtD
Hydroflumethiazide—Anorexia—Doxorubicin—sarcoma	0.0013	0.00284	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Epirubicin—sarcoma	0.00128	0.0028	CcSEcCtD
Hydroflumethiazide—Constipation—Epirubicin—sarcoma	0.00126	0.00276	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Doxorubicin—sarcoma	0.00119	0.00259	CcSEcCtD
Hydroflumethiazide—Urticaria—Epirubicin—sarcoma	0.00117	0.00256	CcSEcCtD
Hydroflumethiazide—Constipation—Doxorubicin—sarcoma	0.00117	0.00255	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Epirubicin—sarcoma	0.00109	0.00237	CcSEcCtD
Hydroflumethiazide—Urticaria—Doxorubicin—sarcoma	0.00108	0.00237	CcSEcCtD
Hydroflumethiazide—Asthenia—Epirubicin—sarcoma	0.00106	0.00231	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Epirubicin—sarcoma	0.00101	0.0022	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Doxorubicin—sarcoma	0.001	0.0022	CcSEcCtD
Hydroflumethiazide—Asthenia—Doxorubicin—sarcoma	0.000978	0.00214	CcSEcCtD
Hydroflumethiazide—Dizziness—Epirubicin—sarcoma	0.000975	0.00213	CcSEcCtD
Hydroflumethiazide—Vomiting—Epirubicin—sarcoma	0.000937	0.00205	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Doxorubicin—sarcoma	0.000933	0.00204	CcSEcCtD
Hydroflumethiazide—Rash—Epirubicin—sarcoma	0.000929	0.00203	CcSEcCtD
Hydroflumethiazide—Dermatitis—Epirubicin—sarcoma	0.000928	0.00203	CcSEcCtD
Hydroflumethiazide—Headache—Epirubicin—sarcoma	0.000923	0.00202	CcSEcCtD
Hydroflumethiazide—Dizziness—Doxorubicin—sarcoma	0.000902	0.00197	CcSEcCtD
Hydroflumethiazide—Nausea—Epirubicin—sarcoma	0.000875	0.00191	CcSEcCtD
Hydroflumethiazide—Vomiting—Doxorubicin—sarcoma	0.000867	0.0019	CcSEcCtD
Hydroflumethiazide—Rash—Doxorubicin—sarcoma	0.00086	0.00188	CcSEcCtD
Hydroflumethiazide—Dermatitis—Doxorubicin—sarcoma	0.000859	0.00188	CcSEcCtD
Hydroflumethiazide—Headache—Doxorubicin—sarcoma	0.000854	0.00187	CcSEcCtD
Hydroflumethiazide—Nausea—Doxorubicin—sarcoma	0.00081	0.00177	CcSEcCtD
